Ai Cure Technologies presents AiView digital health solution at CNS Summit

NewsGuard 100/100 Score

New York City-based Ai Cure Technologies opened the Innovation Showcase at CNS Summit in Boca Raton, Fla, with a presentation of its flagship digital health solution,  AiView™. The interactive computer-vision software makes use of the webcam on a smartphone or tablet computer to automatically monitor medication adherence in clinical trials and ongoing care settings.

Clinical trial coordinators and healthcare providers can use the technology to automatically monitor patient medication adherence in real-time. Using their smartphones or tablets, patients are alerted to take their medication and can activate the system which will confirm their identity, the medication and confirm medication ingestion. The simple process takes 15 seconds to complete. Adherence data are immediately and securely transmitted to a centralized dashboard. Nonadherence events, including missed doses or incorrect medication ingestion, trigger alerts that allow coordinators or providers to intervene immediately, using a variety of integrated communication options.

"Through our patent-pending computer vision technology, we're able to simply and inexpensively automate the process of watching a patient take their medication - otherwise known as directly observed therapy (DOT) - and extend this approach to a population level. This type of monitoring ensures that the validity of clinical trial data is not compromised by medication nonadherence," said Adam Hanina, Chairman and CEO of Ai Cure Technologies, Inc. "We've found that even patients who may be considered high-risk enjoy interacting with the system."

As the system is software-based and does not require any alteration to the medication, AiView can be quickly rolled out into a clinical trial. And unlike self-reported text messaging, the system provides visual confirmation that the medication has been correctly ingested. AiView is commercially available and is currently operational in clinical trials in North America.

AiView is HIPAA and 21 CFR Part 11 compliant.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Empowering Change: How Hologic is Shaping the Future of Women's Healthcare